News
#VKTX — B. Riley Highlights Potential of Viking's Amylin Candidate VK3019 | ThinkSabio
Nov 18, 2026 · ThinkSabio Inc
B. Riley maintained an $85 price target on Viking Therapeutics (VKTX), highlighting early preclinical findings for its amylin candidate VK3019. The reported monkey study showed 12.0% weight loss over 19 days, while the company is also exploring longer-acting molecules that could support less-frequent dosing.
🔹 Key Highlights
Analyst Price Target: B. Riley's reported target is $85.
VK3019 Results: Reported 12.0% weight loss over 19 days in monkey dosing.
Comparison: The update described the result as nearly three times the weight loss achieved by VK2735 in its own comparison and greater than the cited tirzepatide result over eight weeks.
Longer-Acting Candidates: Two backup molecules reportedly have twice the duration of action.
Combination Potential: The findings raise the possibility of a once-monthly combination injection.
VK2735 Data: Cholesterol and triglyceride improvements reportedly persisted after moving from weekly to monthly maintenance dosing.
Upcoming Catalyst: First human VK3019 data are expected in Q4 2026.
Valuation: B. Riley's commentary cited an enterprise value of approximately $2.4 billion.
💡 Why It Matters
VK3019 could provide Viking with another potential growth opportunity beyond VK2735, particularly if longer-acting amylin treatments can support convenient maintenance dosing. However, the 12.0% weight-loss result comes from animal testing and should not be treated as evidence of equivalent human efficacy. First-in-human data will be a key milestone.
🚀 Start Your 7-Day FREE ThinkSabio Trial
https://www.thinksabio.com/
ThinkSabio — Stocks Simplified
Share this post
💬 Comments
Loading comments…
Leave a comment
